newsfilter
← Latest News
GlobeNewswire·

Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan

Deal valued at more than $140 million in upfront and potential milestone payments, plus double-digit royalties.Kyorin obtains exclusive rights to develop and commercialize paridiprubart, an anti-TLR4 monoclonal